The market for next-generation peptides is poised for significant growth but is expected to distribute revenues more broadly across consumer-focused companies rather than generating large wins for any single pharmaceutical firm. Unlike earlier peptide-based drugs such as GLP-1 treatments developed by Novo Nordisk and Eli Lilly that became substantial pharmaceutical blockbusters, newer short-chain amino acid peptides targeting muscle recovery, anti-aging, and other wellness applications are moving toward a consumer goods market model.

According to a recent Citigroup survey, approximately 28 percent of U.S. adults have used one of 12 popular peptides, with an average monthly expenditure of around $90. When extrapolated to the entire adult population, this suggests an $80 billion annual revenue potential within the existing grey market. Currently, regulatory hurdles keep these peptides off-label and unapproved for human consumption, leading to their sale predominantly through online retailers such as BioLongevity and SwissChems, often labeled as “for research purposes only.” However, regulatory shifts may be on the horizon. In July, a U.S. Food and Drug Administration advisory panel recommended permitting domestic production of six out of seven popular peptides, potentially expanding the market further by reducing safety concerns for new users.

Despite the market’s anticipated size, the competitive landscape diverges from traditional pharmaceutical dynamics. The majority of peptides in this emerging category cannot be patented, as their formulations have been public knowledge since the 1990s. This lack of intellectual property protection lowers entry barriers and is attracting a variety of players including compounding pharmacies and virtual health companies like Hims & Hers Health, Ro, and LifeMD.

Marketing and pricing strategies are expected to be decisive factors for market participants. Social media and online advertising are currently significant drivers of consumer awareness of peptide products. With minimal product differentiation, companies may increase spending on branding and promotion to capture market share, potentially reaching levels seen in the consumer goods sector. For context, cosmetic giant L’Oréal is forecast to allocate about a third of its revenue to marketing this year. Price sensitivity is also notable: the Citigroup survey indicates that increasing monthly costs from $50 to $150 could reduce the potential user base by nearly 70 percent, highlighting cost as a major reason for discontinuation.

Among emerging players, Hims may hold some advantages after acquiring its own peptide manufacturing facility, which could streamline production and supply. Nevertheless, those advantages may be challenged if larger consumer conglomerates decide to enter the space, further intensifying competition. Overall, while peptides stand to become a substantial market, the returns are likely to be dispersed among multiple consumer-oriented businesses rather than concentrated in pharmaceutical giants.